Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 1
1978 1
1987 1
1988 1
1990 1
1992 1
1993 2
1995 1
1997 1
1998 1
1999 1
2001 3
2003 6
2004 4
2005 2
2006 2
2007 3
2008 5
2009 7
2010 6
2011 16
2012 19
2013 13
2014 15
2015 15
2016 29
2017 33
2018 60
2019 58
2020 23
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 29238067

299 results
Results by year
Filters applied: . Clear all
Page 1
Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA, Chukkapalli S, Bashllari D, Thomas TT, Van Noord RA, Lawlor ER, Hoenerhoff MJ, Opipari AW, Opipari VP. Newman EA, et al. Cell Death Dis. 2017 Dec 13;8(12):3208. doi: 10.1038/s41419-017-0004-9. Cell Death Dis. 2017. PMID: 29238067 Free PMC article.
Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Newman EA, Lu F, Bashllari D, Wang L, Opipari AW, Castle VP. Newman EA, et al. Mol Cancer Res. 2015 Mar;13(3):470-82. doi: 10.1158/1541-7786.MCR-14-0337. Epub 2015 Jan 6. Mol Cancer Res. 2015. PMID: 25563294 Free article.
MYCN induces neuroblastoma in primary neural crest cells.
Olsen RR, Otero JH, García-López J, Wallace K, Finkelstein D, Rehg JE, Yin Z, Wang YD, Freeman KW. Olsen RR, et al. Oncogene. 2017 Aug 31;36(35):5075-5082. doi: 10.1038/onc.2017.128. Epub 2017 May 1. Oncogene. 2017. PMID: 28459463 Free PMC article.
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A. Schulte JH, et al. Oncogene. 2013 Feb 21;32(8):1059-65. doi: 10.1038/onc.2012.106. Epub 2012 Apr 9. Oncogene. 2013. PMID: 22484425
MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.
Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. Wang T, et al. Cell Death Dis. 2018 Feb 14;9(2):220. doi: 10.1038/s41419-018-0295-5. Cell Death Dis. 2018. PMID: 29445162 Free PMC article.
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV. Muvarak N, et al. Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31. Mol Cancer Res. 2015. PMID: 25828893 Free PMC article.
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G. Colicchia V, et al. Oncogene. 2017 Aug 17;36(33):4682-4691. doi: 10.1038/onc.2017.40. Epub 2017 Apr 10. Oncogene. 2017. PMID: 28394338
Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H, Abdallah J, Nasr Z, Khazen G, Sandler A, Abou-Antoun TJ. Zaatiti H, et al. Int J Oncol. 2018 Mar;52(3):787-803. doi: 10.3892/ijo.2018.4236. Epub 2018 Jan 4. Int J Oncol. 2018. PMID: 29328367 Free PMC article.
299 results
Jump to page